Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Saturday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the subject of a number of other reports. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Thursday, April 3rd. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research note on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Up 1.0 %

Shares of NASDAQ:CTSO opened at $1.03 on Friday. The firm has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.01. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The firm has a market capitalization of $64.38 million, a P/E ratio of -2.86 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The company had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. On average, equities analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Several hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new position in Cytosorbents during the 4th quarter valued at $30,000. Key Client Fiduciary Advisors LLC increased its holdings in shares of Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after purchasing an additional 43,900 shares during the period. Renaissance Technologies LLC raised its position in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Cytosorbents during the fourth quarter worth about $99,000. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.